Instilling confidence in ImmuneOnco's bispecific
The first data are dribbled out, but cross-trial comparisons look uninspiring.
The month ahead: August’s upcoming events
Jazz’s Chimerix buy faces its big test.
Cardiff's questionable plan yields more questions
More data from onvansertib's phase 2 study fail to convince.
Astra’s Neogene investment nosedives
NT-125 is discontinued, while two key Datroway readouts are delayed.
Celcuity's $5m pivot does the job
A Pfizer cast-off could become the company's first marketed drug.
Janux tries to improve on the masking approach
Meanwhile, investors await key clinical data.
Nanjing Leads tests investor appetite for Lag3
But BeOne canned its alcestobart deal in May.
5,000 patients later Roche scraps its TIGIT
Tiragolumab failed the Skyscraper-14 and 03 studies, Roche quietly reveals.
Novel cadherin conjugates enter the clinic
Biopharma's interest in CDH17 and CDH6 continues, courtesy of Lepu and Qilu.
Scancell pivots back to a subgroup
The company claims a 69% response rate with iSCIB1+, but only in a “target population”.
